APO-Bortezomib bortezomib 3.5mg powder for injection vial

Country: Ավստրալիա

language: անգլերեն

source: Department of Health (Therapeutic Goods Administration)

active_ingredient:

bortezomib, Quantity: 3.5 mg

MAH:

Arrotex Pharmaceuticals Pty Ltd

INN:

Bortezomib

pharmaceutical_form:

Injection, powder for

composition:

Excipient Ingredients: mannitol

administration_route:

Subcutaneous, Intravenous

units_in_package:

1

prescription_type:

(S4) Prescription Only Medicine

therapeutic_indication:

Bortezomib, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,Bortezomib, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,Bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy and who have progressive disease.

leaflet_short:

Visual Identification: White to off-white powder; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

authorization_status:

Licence status A

authorization_date:

2015-07-22